A detailed history of Jpmorgan Chase & CO transactions in Opti Nose, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 7,016 shares of OPTN stock, worth $3,367. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,016
Previous 7,945 11.69%
Holding current value
$3,367
Previous $8,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$0.67 - $1.27 $622 - $1,179
-929 Reduced 11.69%
7,016 $4,000
Q2 2024

Aug 12, 2024

SELL
$0.82 - $1.44 $97,906 - $171,933
-119,398 Reduced 93.76%
7,945 $8,000
Q1 2024

May 10, 2024

BUY
$1.17 - $1.94 $88,978 - $147,537
76,050 Added 148.27%
127,343 $185,000
Q4 2023

Feb 12, 2024

SELL
$1.02 - $1.47 $20,713 - $29,851
-20,307 Reduced 28.36%
51,293 $66,000
Q3 2023

Nov 14, 2023

BUY
$0.93 - $1.38 $6,175 - $9,163
6,640 Added 10.22%
71,600 $88,000
Q2 2023

Aug 11, 2023

BUY
$1.11 - $2.05 $49,499 - $91,417
44,594 Added 218.96%
64,960 $79,000
Q1 2023

May 11, 2023

BUY
$1.63 - $2.02 $7,414 - $9,188
4,549 Added 28.76%
20,366 $39,000
Q4 2022

Feb 13, 2023

BUY
$1.68 - $3.7 $16,828 - $37,062
10,017 Added 172.71%
15,817 $29,000
Q3 2022

Nov 14, 2022

BUY
$3.43 - $4.01 $7,305 - $8,541
2,130 Added 58.04%
5,800 $21,000
Q2 2022

Aug 11, 2022

SELL
$1.76 - $3.82 $10,755 - $23,344
-6,111 Reduced 62.48%
3,670 $13,000
Q1 2022

May 11, 2022

BUY
$1.77 - $2.93 $4,375 - $7,242
2,472 Added 33.82%
9,781 $24,000
Q4 2021

Feb 10, 2022

SELL
$1.55 - $3.1 $28,509 - $57,018
-18,393 Reduced 71.56%
7,309 $12,000
Q3 2021

Nov 12, 2021

BUY
$2.35 - $3.16 $60,399 - $81,218
25,702 New
25,702 $77,000

Others Institutions Holding OPTN

About OptiNose, Inc.


  • Ticker OPTN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 83,277,504
  • Market Cap $40M
  • Description
  • OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...
More about OPTN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.